NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
Clinical Trials
84 trialsNCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05601440 2026-03-27
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07203729 2026-03-16
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT02755272 2025-07-04
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT01815242 2025-02-27
ADAPT
West German Study Group
Phase 2 Completed
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT06531447 2024-08-01
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
The National Center of Oncology, Azerbaijan
Phase 2 Active not recruiting
NCT03887130 2024-04-30
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Pierre Fabre Medicament
Phase 2 Completed
NCT00679029 2023-12-11
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Phase 2 Terminated
NCT00244933 2023-06-22
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00323063 2023-03-29
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00128856 2023-03-06
Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT02341911 2022-04-20
TNBC
Fudan University
Phase 2 Unknown
NCT02978716 2022-03-23
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT00193206 2021-11-23
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193050 2021-10-26
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00470249 2021-02-01
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
University of Southampton
Phase 2 Terminated
NCT04681911 2020-12-23
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04517292 2020-08-18
GEP
Fudan University
Phase 2 Unknown
NCT02263495 2020-07-14
EG_PG
Asan Medical Center
Phase 2 Completed
NCT02538432 2019-11-04
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT04143906 2019-10-30
Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT01606748 2019-09-30
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Eli Lilly and Company
Phase 2 Completed
NCT00191243 2019-09-12
Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00462865 2019-04-09
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Brown University
Phase 2 Terminated
NCT00403130 2019-02-20
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
Stanford University
Phase 2 Completed
NCT00005991 2018-11-14
Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00201760 2017-12-27
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02489409 2017-07-17
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer
Xinjiang Medical University
Phase 2 Unknown
NCT00503906 2017-05-12
Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
University of Miami
Phase 2 Completed
NCT00662129 2017-04-17
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00618826 2017-04-14
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00006007 2016-12-07
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00059852 2016-12-07
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00002998 2016-07-13
Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01201265 2016-05-27
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01550848 2015-09-09
A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer
Fudan University
Phase 2 Completed
NCT02544243 2015-09-09
Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT00894504 2015-05-15
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00846027 2014-07-23
A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00159458 2014-05-22
Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer
University of Southern California
Phase 2 Terminated
NCT00493636 2014-05-20
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
Accelerated Community Oncology Research Network
Phase 2 Completed
NCT00193063 2014-03-12
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01045304 2014-01-14
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Sanofi
Phase 2 Completed
NCT00027989 2013-12-18
Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00674206 2013-12-12
A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer
Emory University
Phase 2 Terminated
NCT00212069 2013-12-11
Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer
National University Hospital, Singapore
Phase 2 Completed
NCT00320541 2013-07-22
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
Eli Lilly and Company
Phase 2 Completed